Group 1: Company Overview and Core Products - Guangyuyuan Traditional Chinese Medicine Co., Ltd. has a history of over 500 years, with core products including Gui Ling Ji, Ding Kun Dan, and An Gong Niu Huang Wan, which are recognized for their unique advantages [6][11]. - Gui Ling Ji is referred to as the "living fossil of traditional Chinese medicine," highlighting the company's historical legacy and brand quality [6][11]. Group 2: Market Performance and Financials - In Q3 2024, the company's revenue decreased by 15.52% year-on-year, attributed to a decline in market demand and changes in product policies [8][10]. - The company reported a 7.93% decline in revenue for the first three quarters of 2024, influenced by insufficient market demand and intensified competition [10][8]. Group 3: Marketing and Brand Strategy - The company emphasizes brand building and cultural heritage, focusing on academic promotion and precise targeting of consumer groups [3][4]. - Marketing strategies include collaborations with chain pharmacies, community health services, and educational initiatives to enhance consumer understanding of traditional Chinese medicine [4][3]. Group 4: Product Development and Innovation - The company is committed to continuous research and innovation, actively exploring new channels and ensuring product quality [4][6]. - There is a focus on enhancing the efficacy of products aimed at improving immunity, reproductive health, and liver protection, particularly for middle-aged and elderly populations [2][3]. Group 5: Investor Relations and Corporate Governance - The company maintains open communication with investors, encouraging feedback and suggestions through various platforms [16][18]. - There is a commitment to improving shareholder returns and managing expectations, recognizing shareholders as both owners and consumers of the company [5][10]. Group 6: Future Outlook and Strategic Initiatives - The company plans to leverage national policies to expand its market presence in Southeast Asia, with a focus on enhancing brand influence and market competitiveness [15][14]. - Future strategies include optimizing marketing policies, enhancing service quality, and improving operational efficiency to drive sustainable growth [10][17].

证券代码：600771 证券简称：广誉远 编号：临 2024-040 广誉远中药股份有限公司 关于召开 2024 年第三季度业绩说明会的预告公告 特别提示 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2024 年 11 月 25 日（星期一）15:00-16:00 会议召开地点：价值在线（www.ir-online.cn） 会议召开方式：网络文字互动方式 会 议 问 题 征 集 ： 投 资 者 可 于 2024 年 11 月 22 日 15:00 前 访 问 网 址 https://eseb.cn/1jyei1FP42s 或使用微信扫描下方小程序码进行会前提问，公司将 通过本次业绩说明会，在信息披露允许范围内就投资者普遍关注的问题进行回 答。 （www.ir-online.cn）举办 2024 年第三季度报告业绩说明会，与投资者进行沟通和交 流，广泛听取投资者的意见和建议。 二、说明会召开的时间、地点和方式 会议召开时间：2024 年 11 月 25 日（星期一）15:00-16:00 会议召 ...

广誉远中药股份有限公司舆情管理制度（试行） 第一章 总则 第一条 为了完善广誉远中药股份有限公司（以下简称公司）内部管理制度体系， 提高公司应对各类舆情的规范管理水平和工作效率，建立快速反应和应急处置机制， 及时、妥善处理各类舆情对公司市场形象、商业信誉及正常生产经营活动造成的影响， 切实保护公司及全体投资者合法权益，根据相关法律法规及规范性文件和《公司章程》 等相关规定，结合公司实际情况，制定本制度。 第二条 本制度所称舆情包括： （一）报刊、杂志、电视、广播、网络等媒体、自媒体对公司进行的负面或不实 报道、分析、猜测、恶意抨击等； （二）社会上存在的已经或将给公司形象和信誉造成不良影响的传言或信息； （三）可能或者已经影响社会公众投资者投资判断，造成股价异常波动的未公开信 息或不实信息； （四）其他涉及公司信息披露且可能对公司股票及其衍生品交易价格产生较大影 响的事件信息。 第三条 本制度属于公司具体规章制度，适用于公司总部各部室、各子公司及事 业部。 第二章 舆情管理的组织机构及其工作职责 第四条 公司应对各类舆情实行统一领导、统一组织、快速反应、协同应对。 第五条 公司成立舆情管理工作领导小组（以下简 ...

证券代码：600771 证券简称：广誉远 编号：临 2024-037 广誉远中药股份有限公司（以下简称"公司"）董事会于近日收到副董事长杨波女士 的书面辞职报告，杨波女士因工作调整原因，辞去公司副董事长、董事及董事会各专门委员 会职务，辞职后，杨波女士不再担任上市公司任何职务。根据《公司章程》的相关规定，其 辞职报告自送达公司董事会之日起生效。 公司及董事会对杨波女士在任职期间为公司发展所做出的贡献表示衷心的感谢！ 特此公告。 广誉远中药股份有限公司董事会 二○二四年十月二十五日 广誉远中药股份有限公司 关于副董事长辞职的公告 特别提示 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 ...

Financial Performance - The company's operating revenue for Q3 2024 was ¥233,925,588.87, a decrease of 15.52% compared to ¥273,958,024.48 in the same period last year[4] - Net profit attributable to shareholders for Q3 2024 was ¥11,361,158.38, down 70.98% from ¥14,423,083.20 year-on-year[4] - The net profit after deducting non-recurring gains and losses for Q3 2024 was ¥9,488,994.37, a decrease of 64.19% compared to ¥2,675,325.40 in the previous year[4] - The basic earnings per share for Q3 2024 was ¥0.02, down 75.00% from ¥0.03 in the same period last year[4] - Total operating revenue for the first three quarters of 2024 was CNY 893,525,764.69, a decrease of 7.93% compared to CNY 970,470,739.58 in the same period of 2023[15] - Net profit for the first three quarters of 2024 was CNY 80,327,259.54, compared to CNY 93,614,632.03 in 2023, indicating a decline of 14.14%[15] - The total comprehensive income for Q3 2024 was ¥80,327,259.54, down from ¥93,614,632.03 in Q3 2023, reflecting a decline of 14.1%[16] Cash Flow and Liquidity - The net cash flow from operating activities for the year-to-date period was ¥136,053,785.23, a decline of 62.16% compared to ¥359,515,911.53 in the same period last year[4] - Cash inflows from operating activities totaled ¥1,197,449,684.17 in the first three quarters of 2024, up from ¥1,150,676,072.65 in the same period of 2023, representing a growth of 4.1%[17] - Cash outflows from operating activities increased to ¥1,061,395,898.94 in Q3 2024, compared to ¥791,160,161.12 in Q3 2023, marking a significant rise of 34.2%[17] - The net cash flow from operating activities for the first three quarters of 2024 was ¥136,053,785.23, down 62.2% from ¥359,515,911.53 in the same period of 2023[17] - Cash and cash equivalents at the end of Q3 2024 were ¥135,999,306.73, a decrease from ¥225,853,031.40 at the end of Q3 2023, reflecting a decline of 39.7%[18] - The company reported a significant decrease in cash flow due to increased raw material prices and timely payments to suppliers[7] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,402,750,926.24, down 8.59% from ¥2,628,413,544.42 at the end of the previous year[5] - Total liabilities decreased to CNY 814,559,959.25 in 2024 from CNY 1,120,549,836.97 in 2023, a reduction of 27.24%[14] - The total equity attributable to shareholders increased to CNY 1,567,091,851.02 in 2024 from CNY 1,496,127,641.31 in 2023, an increase of 4.76%[14] - The company received government subsidies amounting to ¥14,914,371.03 year-to-date, which contributed to the financial results[6] Shareholder Information - As of September 30, 2024, the total number of ordinary shareholders is 65,354, with the largest shareholder, Jinchang Investment Co., Ltd., holding 71,508,968 shares, representing 14.61% of the total share capital[8] - The company has a total of 2,724,500 shares directly held by its controlling shareholder, Shennong Technology Group, which represents 0.56% of the total share capital[11] - The company has not reported any changes in the status of pledged, marked, or frozen shares for the top shareholders[9] - The company’s major shareholders have not disclosed any known relationships or agreements that would classify them as acting in concert under the relevant regulations[9] Inventory and Receivables - Accounts receivable decreased to ¥381,395,050.41 from ¥488,346,960.66, reflecting a reduction of about 22%[12] - Inventory increased significantly to ¥761,541,437.18 from ¥569,530,008.23, marking an increase of approximately 33.7%[12] - The company reported a significant increase in other receivables, rising to ¥72,393,238.37 from ¥8,031,217.93, indicating a growth of over 800%[12] Research and Development - Research and development expenses increased to CNY 27,910,261.53 in 2024 from CNY 24,426,723.77 in 2023, representing a growth of 10.16%[15] - The company plans to continue investing in R&D to enhance product offerings and market competitiveness despite the current financial challenges[15] Future Plans - The company plans to increase its shareholding through market transactions, with a planned investment between ¥50 million and ¥100 million over the next 12 months, starting from August 26, 2024[11]

证券代码：600771 证券简称：广誉远 编号：临 2024-039 4、公司全体监事承诺 2024 年第三季度报告所载资料不存在任何虚假记载、误导性 陈述或重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 特此公告。 广誉远中药股份有限公司 第八届监事会第十次会议决议公告 特别提示 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 广誉远中药股份有限公司第八届监事会第十次会议于 2024 年 10 月 15 日以电话、 邮件及其他网络通讯方式发出通知，于 2024 年 10 月 25 日以通讯方式召开。会议应出 席监事 3 名，亲自出席监事 3 名，符合《公司法》及《公司章程》的有关规定。会议由 监事会主席张华中主持，经认真审议，以"同意 3 票，反对 0 票，弃权 0 票"的表决结 果全票通过了《公司 2024 年第三季度报告》。 监事会对《公司 2024 年第三季度报告》进行了审慎审核，认为： 1、公司 2024 年第三季度报告的编制和审议程序符合法律法规、公司章程和公司内 部管理制度的规定。 2、公司 2 ...

证券代码：600771 证券简称：广誉远 编号：临 2024-038 广誉远中药股份有限公司（以下简称"公司"）第八届董事会第十二次会议于 2024 年 10 月 15 日以电话、邮件及其他网络通讯方式向全体董事发出通知，于 2024 年 10 月 25 日以通讯方式召开。会议应出席董事 6 名，实际出席董事 6 名，符合《公司法》及 《公司章程》的有关规定。会议由董事长李晓军主持，经大会认真审议，通过了以下议 案： 一、审议通过《公司 2024 年第三季度报告》 《公司 2024 年第三季度报告》已经董事会审计委员会审议通过，同意将该报告提 交公司董事会审议。 表决情况：同意 6 票，反对 0 票，弃权 0 票。 具体内容详见公司同日在上海证券交易所网站披露的《公司2024年第三季度报告》。 二、审议通过《广誉远中药股份有限公司舆情管理制度（试行）》 广誉远中药股份有限公司 第八届董事会第十二次会议决议公告 特别提示 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 为了完善公司内部管理制度体系，提高公司应对各类舆情的规范管理 ...

Group 1: Product Overview - The company's core products, Gui Ling Ji and Ding Kun Dan, have significant therapeutic effects and are positioned for both health maintenance and treatment [4][5][6]. - Gui Ling Ji is suitable for a wide range of chronic conditions, including over a hundred diseases such as rheumatism, gout, and osteoporosis, enhancing memory and restoring bodily functions [3][4]. - Ding Kun Dan targets women's health, focusing on regulating menstrual cycles and improving overall vitality, with over 5,000 cases collected for clinical research [4][5]. Group 2: Market Strategy - The company is actively collecting treatment cases and conducting targeted marketing strategies to better match consumer needs [4][5]. - Innovative marketing strategies include cultural exploration, digital transformation, and resource collaboration to enhance brand influence and market competitiveness [4][5]. - The company emphasizes brand building and cultural heritage to engage younger consumers and rejuvenate the brand's image [5][6]. Group 3: Financial Performance - The company reported a net profit of over 150 million in other income for the first half of 2024, compared to over 190 million for the entire previous year [8][9]. - The inventory value as of mid-2024 was 694 million, accounting for 44.6% of net assets, reflecting a 21.82% increase from the previous year [14]. - Sales expenses have decreased from 70.11% in 2022 to 44.7% in the first half of 2024, indicating improved cost management [14]. Group 4: Regulatory and Product Development - The company is exploring the possibility of converting Gui Ling Ji from a prescription drug to an OTC product, which requires full disclosure of the formula and compliance with national policies [9][10]. - The unique production techniques of An Gong Niu Huang Wan have been recognized as a national intangible cultural heritage, enhancing its market position [6][7]. - The company is cautious about disclosing proprietary formulas due to their classified status, which impacts its ability to market certain products [10][11]. Group 5: Future Plans and Challenges - The company is focusing on the revitalization of Gui Jiu (turtle wine) and has established a dedicated wine production and marketing company to enhance operational efficiency [8][9]. - There are plans to expand product offerings and explore international markets, although current regulations limit overseas sales [13][14]. - The company aims to improve employee training and attract external talent to enhance operational efficiency and market communication [12][13].

证券代码：600771 证券简称：广誉远 编号：临 2024-036 广誉远中药股份有限公司 关于控股股东首次增持公司股份暨后续增持计划的公告 特别提示 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司于 2024 年 8 月 26 日收到控股股东神农科技集团《关于增持广誉远股票的告知 函》，现将有关情况公告如下： 1 首次增持情况：2024 年 8 月 26 日，广誉远中药股份有限公司（以下简称"公司" "广誉远"）控股股东神农科技集团有限公司（以下简称"神农科技集团"）通 过集中竞价方式增持了公司股票 389,100 股，占公司总股本的 0.079%，本次增 持成交总额 6,427,360 元（不含手续费）。 增持计划基本情况：基于对公司未来发展的信心和长期投资价值的认可，为提 升投资者信心，切实维护中小股东利益和市场稳定，神农科技集团拟实施广誉 远股票增持计划，以更好地支持广誉远未来持续、稳定、健康的发展。神农科 技集团计划自 2024 年 8 月 26 日起 12 个月内，以集中竞价、大宗交易等符合 ...

证券代码：600771 证券简称：广誉远 编号：临 2024-035 广誉远中药股份有限公司 1 会议召开时间：2024 年 08 月 30 日（星期五）15:00-16:00 会议召开地点：价值在线（www.ir-online.cn） 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、说明会类型 广誉远中药股份有限公司（以下简称"公司"）已于 2024 年 8 月 23 日披露了《2024 年半年度报告》及《2024 年半年度报告摘要》。为便于广大投资者更加全面深入地了解 公司经营业绩、发展战略及财务状况等情况，公司定于 2024 年 08 月 30 日（星期五） 15:00-16:00 在"价值在线"（www.ir-online.cn）举办广誉远中药股份有限公司 2024 关于召开 2024 年半年度业绩说明会的预告公告 特别提示 会议召开方式：网络文字互动方式 会议问题征集：投资者可于 2024 年 08 月 28 日 15：00 前通过访问网址 https://eseb.cn/1haVHfXY33a ...